Erythropoietin drives breast cancer progression by activation of its receptor EPOR.
Chan KK, Matchett KB, Coulter JA, Yuen HF, McCrudden CM, Zhang SD, Irwin GW, Davidson MA, Rülicke T, Schober S, Hengst L, Jaekel H, Platt-Higgins A, Rudland PS, Mills KI, Maxwell P, El-Tanani M, Lappin TR.
Chan KK, et al. Among authors: rudland ps.
Oncotarget. 2017 Jun 13;8(24):38251-38263. doi: 10.18632/oncotarget.16368.
Oncotarget. 2017.
PMID: 28418910
Free PMC article.